Document is current
Any future updates will be listed below
-
Authors
Nia, Hadi T. https://orcid.org/0000-0003-1970-9901
Datta, Meenal https://orcid.org/0000-0001-5727-8992
Seano, Giorgio https://orcid.org/0000-0002-7294-302X
Zhang, Sue
Ho, William W. https://orcid.org/0000-0002-1755-833X
Roberge, Sylvie
Huang, Peigen https://orcid.org/0000-0002-3184-6493
Munn, Lance L.
Jain, Rakesh K. https://orcid.org/0000-0001-7571-3548
- License Information
-
More Information
Article History
Received: 8 December 2018
Accepted: 6 April 2020
First Online: 17 July 2020
Competing interests
: R.K.J. received an honorarium from Amgen; consultant fees from Chugai, Enlight, Merck, Ophthotech, Pfizer, SPARC, SynDevRx, and XTuit; owns equity in Enlight, Ophthotech, and SynDevRx; and serves on the boards of trustees of Tekla Healthcare Investors, Tekla Life Sciences Investors, Tekla Healthcare Opportunities Fund, and Tekla World Healthcare Fund. No funding or reagents from these companies were used in this study.
